ANDA 214207, held by Epic Pharma. Doxycycline Hyclate.
As of Nov 21, 2026, ANDA 214207 (Doxycycline Hyclate), held by Epic Pharma, was first approved by FDA on Dec 16, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2020 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters